Affiliation:
1. G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far-Eastern Branch of the Russian Academy of Science, Vladivostok 690022, Russia
Abstract
Sepsis is a life-threatening complication of an infectious process that results from the excessive and uncontrolled activation of the host’s pro-inflammatory immune response to a pathogen. Lipopolysaccharide (LPS), also known as endotoxin, which is a major component of Gram-negative bacteria’s outer membrane, plays a key role in the development of Gram-negative sepsis and septic shock in humans. To date, no specific and effective drug against sepsis has been developed. This review summarizes data on LPS-binding proteins from marine invertebrates (ILBPs) that inhibit LPS toxic effects and are of interest as potential drugs for sepsis treatment. The structure, physicochemical properties, antimicrobial, and LPS-binding/neutralizing activity of these proteins and their synthetic analogs are considered in detail. Problems that arise during clinical trials of potential anti-endotoxic drugs are discussed.
Subject
Drug Discovery,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Pharmaceutical Science
Reference153 articles.
1. Bacterial lipopolysaccharides and innate immunity;Alexander;J. Endotoxin Res.,2001
2. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia;Lynn;J. Infect. Dis.,2003
3. Marine compounds with therapeutic potential in Gram-negative sepsis;Davydova;Mar. Drugs,2013
4. Endotoxin neutralizing peptides;Jerala;Curr. Top. Med. Chem.,2004
5. Recent advances in the innate immunity of invertebrate animals;Iwanaga;J. Biochem. Mol. Biol.,2005